Register for free to listen to this article
Listen with Speechify
0:00
2:00
ORLANDO, Fla.—Results of the Systems Toxicology Computational Challenge (STCC) reportedly have demonstrated how transcriptomics information present in the blood can be used to predict whether people have been exposed or not exposed to specific toxicants. The findings have been said to have important implications across a range of disciplines, including diagnostics, toxicological risk assessment and personalized medicine. Challenge participants used their own computational techniques to make their predictions, with best-performers achieving accuracy of up to 95 percent. A total of 135 scientists from around the world registered for the challenge.
                        
The STCC is the latest to be run under the sbv IMPROVER project umbrella, a crowdsourcing initiative led and funded by Philip Morris International that is designed to test and verify scientific methods and results.
 
“The real-world application of models based on blood gene expression markers for predictive classification in toxicology is uniquely challenging,” said Dr. Carine Poussin of the Computational Biology division of Philip Morris International. “The difficulty resides in the identification of relevant markers in blood after chemical exposure and the low success of correct classification when predictive models are applied on new individual blood samples. Furthermore, most preclinical toxicological in-vivo studies are conducted in rodents, adding a degree of complexity when applying the results to humans. The Systems Toxicology Computational Challenge has explored these questions and helped to increase our understanding of what is necessary to reach higher levels of predictability and robustness in both humans and across species.”
 
The STCC aimed to verify that robust markers could be extracted from blood gene expression data that would distinguish current tobacco smokers from nonsmokers, and then discriminate nonsmokers as former smokers and “never smokers.” This question was addressed in two sub-challenges, the first one looking at human data only, the second one investigating human and mouse data together. Anonymized participants’ submissions were scored against a gold-standard dataset. Final results and team rankings were reviewed and approved by an independent expert scoring review panel.
 
Participants were successful in developing models with a high level of predictive performance in distinguishing current tobacco smokers from nonsmokers. Predicting whether nonsmokers were former smokers or never smokers was more challenging, suggesting that these two groups are likely to have similar gene expression profiles.
 
“While the Systems Toxicology Computational Challenge asked participants to make predictions on smoking status, the techniques that participants put forward could in theory be applied to make predictions on exposure to any toxicant or external stimuli,” said Dr. Julia Hoeng, director of systems toxicology for Biological Systems Research at Philip Morris International. “Importantly, the challenge rules stipulated that models had to be applicable to new individual blood samples without the need for adjustments, making them potentially suitable for ready-to-use diagnostic tools.”

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue